Literature DB >> 19273971

KSHV/HHV8-associated intestinal Kaposi's sarcoma in patient with ulcerative colitis receiving immunosuppressive drugs: report of a case.

Magali Svrcek1, Emmanuel Tiret, Malika Bennis, Philippe Guyot, Jean-François Fléjou.   

Abstract

Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), has been identified in all four forms of Kaposi's sarcoma (classic, endemic, HIV-associated and iatrogenic). We report the rare case of an intestinal (small intestine and rectosigmoid) Kaposi's sarcoma in a 62-year-old HIV-negative man with ulcerative colitis. This patient was receiving immunosuppressive therapy with steroids and azathioprine. To date, the causative role of KSHV/HHV8 in the pathophysiology of Kaposi's sarcoma associated with ulcerative colitis has only been proven for cutaneous lesions but not for intestinal lesions of Kaposi's sarcoma. We report for the first time, the expression of HHV8 (by using immunohistochemistry) in colonic Kaposi's sarcoma in a patient with an ulcerative colitis-related tumor. The patient underwent a total proctocolectomy. At laparotomy, numerous Kaposi's sarcoma lesions were found in the small intestine, which were left in situ. Forty months after surgery and following withdrawal of immunosuppressive therapy, the patient had no evidence of any disease and a normal abdominal and thoracic CT scan. Cases of colorectal Kaposi's sarcoma complicating inflammatory bowel disease should be managed with a conservative approach and discontinuation of the immunosuppressive treatment. However, discontinuation of the immunosuppression is not always possible and in those cases chemotherapy may be indicated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273971     DOI: 10.1007/DCR.0b013e318197217f

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

1.  [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus].

Authors:  S Krengel; I Satzger; M Alter; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

2.  Skin cancers associated with autoimmune conditions among elderly adults.

Authors:  E Lanoy; E A Engels
Journal:  Br J Cancer       Date:  2010-06-15       Impact factor: 7.640

3.  Human herpesvirus-8 positive iatrogenic Kaposi's sarcoma in the setting of refractory ulcerative colitis.

Authors:  Erica Duh; Sean Fine
Journal:  World J Clin Cases       Date:  2017-12-16       Impact factor: 1.337

4.  Pleomorphic undifferentiated soft tissue sarcoma in patient with long standing inflammatory bowel disease.

Authors:  Loredana Labinac-Peteh; Robert Terlević; Božo Krušlin
Journal:  Autops Case Rep       Date:  2018-04-18

5.  Iatrogenic Kaposi sarcoma of the terminal ileum following short-term treatment with immunomodulators for Crohn disease: A case report.

Authors:  Elisa Stasi; Stefania De Santis; Elisabetta Cavalcanti; Raffaele Armentano
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Cyclosporine-Induced Kaposi Sarcoma in a Patient With Ulcerative Colitis.

Authors:  Lindsay M Clarke; Karan Chawla; Nadeem Tabbara; Daniel Szvarca; Anna Stachura; Brian Theisen; Matthew Chandler; Marie L Borum
Journal:  ACG Case Rep J       Date:  2021-05-26

7.  Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma.

Authors:  Emilien Billon; Anne-Marie Stoppa; Lena Mescam; Massimo Bocci; Audrey Monneur; Delphine Perrot; François Bertucci
Journal:  Clin Sarcoma Res       Date:  2018-06-11

Review 8.  Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: a case report and review of the literature.

Authors:  Valerio Papa; Maria Cristina Giustiniani; Loris Riccardo Lopetuso; Alfredo Papa
Journal:  BMC Gastroenterol       Date:  2020-03-24       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.